Princeton Alpha Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Princeton Alpha Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-3,500	Closed	-$383K	–	375
2017 Q1	$383K	Buy	+3,500	New	+$308K	0.13%	278
2016 Q1	–	Sell	-2,864	Closed	-$360K	–	951
2015 Q4	$360K	Sell	2,864 -2,310	-45%	-$279K	0.06%	436
2015 Q3	$539K	Buy	5,174 +2,523	+95%	+$324K	0.11%	278
2015 Q2	$327K	Buy	+2,651	New	+$334K	0.06%	421
2014 Q2	–	Sell	-3,822	Closed	-$270K	–	856
2014 Q1	$270K	Buy	+3,822	New	+$303K	0.08%	389

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Princeton Alpha Management's VRTX Position: Q2 2017 in Review

Princeton Alpha Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2017, closing a stake of 3,500 shares — an estimated $383K sold.

Princeton Alpha Management first reported a position in VRTX in Q1 2014 and held it in 5 quarters. The position peaked at $539K in Q3 2015. 582 funds tracked by Wall St. Rank hold VRTX as of Q2 2017.

Princeton Alpha Management reported no remaining Vertex Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Princeton Alpha Management sold 3,500 Vertex Pharmaceuticals shares in Q2 2017, an estimated $383K.
Princeton Alpha Management first reported a position in Vertex Pharmaceuticals in Q1 2014 and held it in 5 quarters.
Princeton Alpha Management's Vertex Pharmaceuticals position peaked at $539K in Q3 2015.
582 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2017.

Based on Princeton Alpha Management's 13F filing for Q2 2017.